Will CVS Deal Extension Change McKesson Stock Narrative

• EPIC Pharmacies previously introduced a new wholesale model that lets independent pharmacies pick McKesson or Morris & Dickson as primary partners, while McKesson separately agreed in principle to extend its pharmaceutical distribution relationship with CVS Health through June 2032.
• The extended CVS Health agreement gives McKesson longer visibility on a large distribution channel and this may influence how investors view the reshaping of its portfolio around core pharmaceutical and oncology services.
• We will now look at how McKesson's extended CVS Health distribution deal could influence the broader investment narrative around the business.

Scan how McKesson's wholesale and distribution moves compare with peers by reviewing a curated list of list of solid balance sheet and fundamentals (25 results) that are poised for consistent execution across supply chains.

McKesson Investment Narrative Recap

To own McKesson, you need to be comfortable with a low margin but high volume distributor that is leaning harder into oncology, specialty and prescription technology. The near term story revolves around keeping large contracts in place and executing on the oncology and RxTS build out, while managing capital returns against a relatively high debt load.

Regulatory pressure on drug pricing, cyber security fallout and any slowdown in GLP 1 related access volumes remain the biggest operational swing factors. The extended CVS Health agreement looks meaningful for short term visibility on distribution volumes. It does not remove those risks, but it can reduce contract renewal uncertainty.

The agreement in principle to extend McKesson’s pharmaceutical distribution partnership with CVS Health through June 2032 is the key announcement here. That deal touches mail order, specialty and retail pharmacies plus distribution centers, so it directly aligns with the firm’s focus on core pharmaceutical and oncology platforms.

For you as an investor, this kind of long dated distribution arrangement can clarify one of the main catalysts: steady fee for service volume flowing through North American Pharmaceutical, while you weigh it against ongoing risks. It also sits alongside oncology expansion and RxTS growth as operational levers that could matter for earnings power over time.

Analysts expect McKesson's revenue to reach $502.4b and earnings to come in at $6.3b by 2029. This implies 6.9% yearly revenue growth and an earnings increase of about $1.7b from the current $4.6b base.

Uncover how McKesson's fair value points to a 4% potential upside to its current price before the market closes that discount.

Exploring Other Perspectives

Fair value estimates for McKesson from 3 private investors in the Simply Wall St Community span roughly US$980 to US$1,661, so you are looking at a wide bracket of expectations. Those views sit beside risks such as tighter drug pricing rules or higher cyber related costs, which could affect how future cash flows are assessed. To see how sharply opinions can differ, explore several of these alternative viewpoints before settling on your own scenario for the business.

Explore 2 other McKesson fair value estimates, including one that suggests there could be as much as 77% upside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your McKesson research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for McKesson. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate McKesson's overall financial health at a glance.

Looking for more McKesson-sized investment ideas?

If the McKesson story has sharpened your thinking about contracts, balance sheets and execution risk, it can be useful to widen the lens and compare it with other businesses that fit different profiles. The Simply Wall St Screener is built for exactly that, letting you move quickly from one clear thesis to the next without getting buried in noise.

• If you prefer to focus on financial resilience first and everything else second, start with a 31 resilient stocks with low risk scores that can help you narrow in on companies where balance sheet strength and risk scores are front and centre.
• If valuation discipline is your priority, widen your opportunity set with a curated 29 high quality undervalued stocks that filters for businesses combining quality fundamentals with prices that may not fully reflect them.
• For readers hunting for ideas the broader market has not crowded into yet, use a 20 high quality undiscovered gems to surface under-the-radar stocks with solid underlying numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com